Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + estramustine
- Development stage
- Unknown
- Lead developer
- Saint Barnabas Medical Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Paclitaxel + estramustine is a combination chemotherapy regimen investigated for the treatment of hormone-refractory prostate cancer (HRPC). Paclitaxel, a taxane, acts as a microtubule-stabilizing agent that binds to the beta-subunit of tubulin, leading to the arrest of the cell cycle in the G2/M phase and subsequent apoptosis. Estramustine phosphate sodium is a dual-action agent consisting of a conjugate of estradiol and nornitrogen mustard; it functions by binding to microtubule-associated proteins (MAPs) and tubulin to inhibit microtubule assembly, while also exerting hormonal effects through the estrogen receptor. This combination was evaluated in a Phase II clinical trial led by St. Barnabas Medical Center to determine its efficacy in patients with metastatic prostate cancer that had progressed despite hormone therapy, aiming to exploit the complementary mechanisms of microtubule disruption to overcome treatment resistance.
- Brand names
- TaxolEmcyt
- Other names
- paclitaxel and estramustineestramustine and paclitaxelpaclitaxel plus estramustine
02
Targets
TUBB (Tubulin (alpha and beta subunits))ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on paclitaxel + estramustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + estramustine.